A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

NCT02772822 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: SCT400 plus CHOP
DRUG: Rituximab plus CHOP

Sponsor

Sinocelltech Ltd.